Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Wilms Tumor 5Rhabdoid Tumor 5Osteosarcoma 5Neuroectodermal Tumors, Primitive, Peripheral 5Neuroblastoma 5Medulloblastoma 5Lymphoma, Non-Hodgkin 5Histiocytosis, Langerhans-Cell 5Hepatoblastoma 5Glioma 5Ependymoma 5Sarcoma 4Rhabdomyosarcoma 4Central Nervous System Neoplasms 4Sarcoma, Ewing 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neuroendocrine Tumors 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Burkitt Lymphoma 2Xanthogranuloma, Juvenile 1Thyroid Cancer, Papillary 1Non functioning pancreatic endocrine tumor 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Lymphoma 1Histiocytic Sarcoma 1Familial ependymoma 1Breast Neoplasms 1Anus Neoplasms 1

Interventions

Letrozole 25Fulvestrant 25Specimen Handling 19ribociclib 16Capecitabine 16pembrolizumab 14palbociclib 14Paclitaxel 14Trastuzumab 13Carboplatin 13exemestane 12abemaciclib 12Tamoxifen 12Anastrozole 12Magnetic Resonance Spectroscopy 11trastuzumab deruxtecan 8pertuzumab 8Biopsy 8Goserelin 7inavolisib 6giredestrant 6Cyclophosphamide 6130-nm albumin-bound paclitaxel 6patritumab deruxtecan 5eribulin 5elacestrant 5Taxes 5Standard of Care 5Radiotherapy 5Gonadotropin-Releasing Hormone 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × Phantoms, Imaging × 30 days × Clear all
NCT02849496 2026-05-22

Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
81 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡